Anti-Cancer Activity of Brachyuran Crab Dromia dehaani (Rathbun, 1923)

Abstract

Marine chemotherapy is well recognized now a days and profound development has been achieved by researchers to deal with different molecular pathways of tumors. In the present study, anticancer activity of the hemolymph of brachyuran crab D. dehaani was assayed with standard MTT colorimetric procedure against a range of human cell lines viz., HepG2, HT-29, rhabdomyosarcoma and A549. Cell viability was evaluated by 3-(4, 5-Dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) assay. Cytotoxicity was assessed by the morphological characteristics were analyzed through phase contrast microscope. The results exhibited remarkable cytotoxicity against HepG2 cells. The results obtained from the MTT assay showed that the tested samples were significantly reduced the viability of all the tested cell lines in a dose-dependent manner upon 24 h of exposure, the results were recorded in IC 50 . The present results revealed that the brachyuran crab D. dehaani could be a potential alternative agent for human cancer therapy.

Antiproliferative and antioxidant activities of the edible crab Callinectes sapidus hepatopancreas and hemolymph extracts

“…Similar previous studies have reported the antitumor effects of hemolymph in other crabs like Atergatis roseus & Eriphia verrucosa (Salama and Mona, 2018), Scylla serrata (Pramanik et al, 2010) and Dromia dehaani (Priya and Ravichandr, 2015a;RethnaPriya et al, 2019). These antiproliferative activities of hemolymph were attributed to glycoproteins such as lectins and hemocyanin with molecular weights of ~75 KDa.…”